<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPP</journal-id>
<journal-id journal-id-type="hwp">sptpp</journal-id>
<journal-title>Therapeutic Advances in Psychopharmacology</journal-title>
<issn pub-type="ppub">2045-1253</issn>
<issn pub-type="epub">2045-1261</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2045125312470130</article-id>
<article-id pub-id-type="publisher-id">10.1177_2045125312470130</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Poletti</surname><given-names>Michele</given-names></name>
<aff id="aff1-2045125312470130">Department of Neuroscience, University of Pisa, via Roma 55, Pisa, Italy</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonuccelli</surname><given-names>Ubaldo</given-names></name>
<aff id="aff2-2045125312470130">Department of Neuroscience, University of Pisa, via Roma 55, Pisa, Italy</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2045125312470130"><email>michelepoletti79@gmail.com</email>; <email>u.bonuccelli@med.unipi.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>3</volume>
<issue>2</issue>
<fpage>101</fpage>
<lpage>113</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The spatiotemporal progression of dopamine depletion in Parkinson’s disease (PD) provides a special model for assessing dopaminergic effects on neural systems with differential baseline dopamine levels. This study aims at reviewing cognitive effects of dopaminergic stimulation in PD. While considering dopaminergic drugs (levodopa or dopamine agonists), temporal intervals (acute or chronic) and cognitive domains, we found that empirical evidence was almost focused on acute effects of levodopa on executive functions. The paucity of empirical evidence suggests that no meaningful conclusions can be actually drawn and further research is needed in relation to: (1) other cognitive domains; (2) the acute cognitive effects of dopamine agonists, as compared with levodopa; (3) possible differences between cognitive effects of different dopamine agonists; (4) the cognitive effects of chronic dopaminergic therapies. The latter issue is of particular clinical interest considering that many PD patients present a mild cognitive impairment: is this cognitive feature worsened or improved by the prolonged dopaminergic therapy? In addition to the potential risk of inducing dyskinesia and behavioral side effects such as impulse control disorders, also cognitive effects of prolonged dopaminergic treatments should be taken in account by clinicians in order to anticipate or to delay their prescription to PD patients.</p>
</abstract>
<kwd-group>
<kwd>acute cognitive effect</kwd>
<kwd>chronic cognitive effect</kwd>
<kwd>cognition</kwd>
<kwd>dopamine agonists</kwd>
<kwd>executive functions</kwd>
<kwd>levodopa</kwd>
<kwd>Parkinson’s disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2045125312470130" sec-type="intro">
<title>Introduction</title>
<p>Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor (bradykinesia, rigidity and resting tremors) and nonmotor symptoms (cognitive impairment, affective and behavioral disturbances, impairment of the autonomic nervous system) [<xref ref-type="bibr" rid="bibr15-2045125312470130">Chaudhury <italic>et al</italic>. 2006</xref>]. Cognitive impairments may be present at an early stage in newly diagnosed drug-naïve patients [<xref ref-type="bibr" rid="bibr76-2045125312470130">Poletti <italic>et al</italic>. 2012b</xref>], with deficits being most prominent in the domains of executive functions, episodic memory and visuospatial functions [<xref ref-type="bibr" rid="bibr66-2045125312470130">Muslimovic <italic>et al</italic>. 2005</xref>]. Prospective studies showed that up to 75–80% of PD patients may eventually develop dementia during the course of the disease, with akinetic-dominant phenotype, early presence of hallucinations and cognitive impairment being the risk factors [<xref ref-type="bibr" rid="bibr1-2045125312470130">Aarsland <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr80-2045125312470130">Santangelo <italic>et al</italic>. 2007</xref>].</p>
<p>Considering the severe impact of cognitive impairment on the quality of life of PD patients and their families [<xref ref-type="bibr" rid="bibr83-2045125312470130">Schrag <italic>et al</italic>. 2000</xref>], the investigation of factors that may prevent, improve or worsen cognitive impairment represents an important topic in the management of these patients. In this perspective, dopaminergic drugs, representing the gold-standard therapy for motor symptoms of PD patients, may affect their cognitive status [<xref ref-type="bibr" rid="bibr17-2045125312470130">Cools, 2006</xref>]. Although both levodopa and dopamine agonists stimulate dopamine receptors, they have different pharmacokinetic characteristics, with levodopa providing a mainly phasic dopaminergic stimulation and dopamine agonists providing a tonic dopaminergic stimulation [<xref ref-type="bibr" rid="bibr10-2045125312470130">Bonuccelli and Pavese, 2006</xref>; <xref ref-type="bibr" rid="bibr72-2045125312470130">Poewe <italic>et al</italic>. 2010</xref>]. Furthermore, different dopamine agonists (e.g. pramipexole, ropinirole, pergolide) have distinct receptor binding and pharmacokinetic characteristics, presenting different affinities for dopamine receptors [<xref ref-type="bibr" rid="bibr71-2045125312470130">Perachon <italic>et al</italic>. 1999</xref>].</p>
<p>This review aims at providing an update of empirical evidence on the cognitive effects of dopaminergic drugs on PD patients. Before presenting and discussing findings of empirical studies, the neuropathological bases of cognitive impairment in PD are presented in the following section.</p>
<sec id="section2-2045125312470130">
<title>Neuropathological bases of cognitive dysfunction in PD</title>
<p>PD is primarily caused by loss of dopaminergic neurons in the nigrostriatal pathway, reducing dopamine levels in the striatum [<xref ref-type="bibr" rid="bibr48-2045125312470130">Hughes <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr51-2045125312470130">Kish <italic>et al</italic>. 1988</xref>]. This dopamine depletion has an impact on the functioning of four frontostriatal networks [<xref ref-type="bibr" rid="bibr2-2045125312470130">Alexander <italic>et al</italic>. 1986</xref>; <xref ref-type="bibr" rid="bibr90-2045125312470130">Yeteran and Pandya, 1991</xref>] involved in motor, cognitive, affective and motivational aspects of behavior [<xref ref-type="bibr" rid="bibr16-2045125312470130">Chudasama and Robbins, 2006</xref>; <xref ref-type="bibr" rid="bibr68-2045125312470130">Owen, 2004</xref>]. Two of these circuits have been mainly investigated and have been related in cognitive deficits of PD patients: the ‘dorsolateral’ circuit including the dorsolateral prefrontal cortex (DLPFC), the striatum (dorsolateral caudate nucleus), the globus pallidus (dorsomedial) and the thalamus; the ‘orbital’ circuit including the orbitofrontal cortex (OFC), the striatum (ventromedial caudate nucleus), the globus pallidus (dorsomedial) and the thalamus. Within each circuit, two loops connect the striatum with the prefrontal cortex (PFC): a direct excitatory loop and an indirect inhibitory loop [<xref ref-type="bibr" rid="bibr2-2045125312470130">Alexander <italic>et al</italic>. 1986</xref>; <xref ref-type="bibr" rid="bibr90-2045125312470130">Yeteran and Pandya, 1991</xref>].</p>
<p>Frontostriatal circuits are involved in ‘executive functions’, necessary for an appropriate, contextual goal-directed behavior, allowing us to formulate goals with regard to their consequences, to generate multiple response alternatives, to choose and to initiate appropriate actions, to self-monitor the adequacy and correctness of these actions, to correct and modify them when conditions change and finally to persist in the face of distractions [<xref ref-type="bibr" rid="bibr61-2045125312470130">Miyake and Friedman, 2012</xref>].</p>
<p>The impairment of executive functions that characterizes most of PD patients from early disease stages [<xref ref-type="bibr" rid="bibr66-2045125312470130">Muslimovic <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr76-2045125312470130">Poletti <italic>et al</italic>. 2012b</xref>] is not primarily due to a direct neuropathology of PFC, but to reduced dopaminergic striatal stimulation, disrupting the physiological functioning of frontostriatal circuits. Anatomical and neuropathological evidences suggest that the evolving pattern of executive impairment in PD might be explained by considering the spatiotemporal progression of dopamine depletion within the striatum, and in relation to the terminal distribution of its cortical afferents [<xref ref-type="bibr" rid="bibr17-2045125312470130">Cools, 2006</xref>; <xref ref-type="bibr" rid="bibr68-2045125312470130">Owen, 2004</xref>]. In the early clinical stages of PD the dopamine depletion is greatest in the foremost dorsolateral extent of the head of the caudate nucleus, an area involved in the ‘dorsolateral’ frontostriatal circuit. Executive functions related to this frontostriatal circuit include functions of attentional control, such as working memory, set-switching and planning, and are usually impaired from the early stages of PD [<xref ref-type="bibr" rid="bibr81-2045125312470130">Sawamoto <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr79-2045125312470130">Rowe <italic>et al</italic>. 2008</xref>]. In the early clinical stages of PD the orbital frontostriatal circuit and the related executive functions, providing a reward-based control of behavior, are mostly preserved [<xref ref-type="bibr" rid="bibr75-2045125312470130">Poletti <italic>et al</italic>. 2010</xref>]. With the progression of disease, the dopamine depletion impairs also the orbital-frontostriatal circuit, probably resulting in an impairment of related executive functions, although these stages of PD have been scarcely investigated by the neuropsychological point of view [<xref ref-type="bibr" rid="bibr73-2045125312470130">Poletti and Bonuccelli, 2012</xref>].</p>
<p>Summarizing, temporal and spatial asymmetries of dopamine depletion and their relation with cognition during the progression of the PD-related neuropathology determine the differential cognitive effects of dopaminergic medication on executive functions in PD. The impairment of executive functions represents the core cognitive feature of PD patients and is clearly related to the nigrostriatal degeneration, as suggested by the correlation between the severity of executive dysfunction and the severity of bradykinesia [<xref ref-type="bibr" rid="bibr29-2045125312470130">Domellof <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr76-2045125312470130">Poletti <italic>et al</italic>. 2012b</xref>], considered the best motor sign of nigrostriatal degeneration [<xref ref-type="bibr" rid="bibr88-2045125312470130">Vingerhoerts <italic>et al</italic>. 1997</xref>]. Although often subtle, deficits may involve other cognitive functions at an early stage, such as memory, language and visuospatial functions [<xref ref-type="bibr" rid="bibr66-2045125312470130">Muslimovic <italic>et al</italic>. 2005</xref>]: these deficits are probably due not only to the indirect effect of executive dysfunction on them, but also to an early cortical neuropathological involvement of posterior regions [<xref ref-type="bibr" rid="bibr47-2045125312470130">Hosokai <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr55-2045125312470130">Lyoo <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr67-2045125312470130">Nobili <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr69-2045125312470130">Pappatà <italic>et al</italic>. 2011</xref>]. With the neuropathological progression of the disease, the widespread cortical diffusion of Lewy bodies [<xref ref-type="bibr" rid="bibr11-2045125312470130">Braak <italic>et al</italic>. 2003</xref>] produces a more severe cognitive impairment, involving several cognitive functions, and often leading to dementia [<xref ref-type="bibr" rid="bibr1-2045125312470130">Aarsland <italic>et al</italic>. 2003</xref>].</p>
</sec>
</sec>
<sec id="section3-2045125312470130" sec-type="methods">
<title>Methods</title>
<p>We performed a systematic review of the literature focusing on studies identified in the electronic databases ISI Web of Knowledge, Medline and PsychInfo and published in English language until August 2012. Keywords used for search were ‘Parkinson’s disease’ combined with a term related to dopaminergic drugs (in alphabetical order: ‘apomorphine’, ‘bromocriptine’, ‘cabergolina’, ‘dopamine agonist’, ‘levodopa’, ‘pergolide’, ‘pramipexole’, ‘ropinirole’, ‘rotigotine’) and a term related to cognitive functioning (in alphabetical order: ‘cognition’, ‘executive functions’, ‘language’, ‘memory’, ‘neuropsychology’, ‘prefrontal functions’, ‘visuospatial functions’, ‘working memory’). Studies identified in electronic databases were distinguished on the basis of their methodology in studies investigating acute cognitive effects <italic>versus</italic> studies investigating chronic cognitive effects. Studies investigating acute cognitive effects adopt a methodology of comparing cognitive performances in ‘on’ and ‘off’ conditions: ‘on’ condition means that patients take their dopaminergic medication and then are tested, while ‘off’ condition means that patients are tested when they have abstained from dopaminergic medication for a minimum of hours (usually at least 12 hours). Studies investigating chronic cognitive effects adopt a methodology of a longitudinal assessment of patients.</p>
</sec>
<sec id="section4-2045125312470130" sec-type="results">
<title>Results</title>
<p>The systematic review of electronic databases identified 22 studies designed to assess the cognitive effects of acute dopaminergic stimulation in PD patients and 3 studies designed to assess the cognitive effects of chronic dopaminergic stimulation.</p>
<sec id="section5-2045125312470130">
<title>Acute dopaminergic stimulation</title>
<p>The main empirical findings of the 21 studies investigating cognitive effects of acute dopaminergic stimulation on PD patients are summarized in <xref ref-type="table" rid="table1-2045125312470130">Table 1</xref>. A preliminary survey identified two common characteristics among these studies. First, almost all studies investigated the acute cognitive effects comparing performances of patients ‘on’ and ‘off’ dopaminergic therapies. Second, considering the main role played by the dopaminergic systems on executive functions, almost all studies investigated the cognitive effects of dopaminergic therapies exclusively on them</p>
<table-wrap id="table1-2045125312470130" position="float">
<label>Table 1.</label>
<caption>
<p>Studies investigating acute cognitive effects of levodopa and dopamine agonists in early and moderate PD patients.</p>
</caption>
<graphic alternate-form-of="table1-2045125312470130" xlink:href="10.1177_2045125312470130-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Dopaminergic drug</th>
<th align="left">Sample (<italic>n</italic>)</th>
<th align="left">Main effect of dopaminergic drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5"><xref ref-type="bibr" rid="bibr53-2045125312470130">Kulisevsky <italic>et al</italic>. [1996]</xref></td>
<td rowspan="5">Levodopa</td>
<td rowspan="5">20 PD (10 stable 10 with wearing off)</td>
<td>In the whole group:</td>
</tr>
<tr>
<td>↑working memory (diminished time response)</td>
</tr>
<tr>
<td>↑set-shifting (diminished time response in the extradimensional matching test (set-shifting)</td>
</tr>
<tr>
<td>↑ cognitive flexibility (diminished time response in the WCST)</td>
</tr>
<tr>
<td>In the wearing-off subgroup ↓ cognitive flexibility (less achieved categories and more perseverative errors in the WCST</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr19-2045125312470130">Cools <italic>et al</italic>. [2001]</xref></td>
<td rowspan="2">Levodopa</td>
<td rowspan="2">29 PD 70 HC</td>
<td>↑ Task set-switching</td>
</tr>
<tr>
<td>↓ Probabilistic reversal learning</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr24-2045125312470130">Cools <italic>et al</italic>. [2002b</xref>]</td>
<td rowspan="2">Levodopa</td>
<td rowspan="2">11 PD</td>
<td>↑ Planning</td>
</tr>
<tr>
<td>↑ Working memory</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr65-2045125312470130">Muller <italic>et al</italic>. [2002]</xref></td>
<td>Apomorphine</td>
<td>26 PD</td>
<td>↓ Simple reaction time</td>
</tr>
<tr>
<td rowspan="6"><xref ref-type="bibr" rid="bibr12-2045125312470130">Brusa <italic>et al</italic>. [2003]</xref></td>
<td rowspan="6">Levodopa Pramipexole</td>
<td rowspan="6">20 PD</td>
<td>Levodopa:</td>
</tr>
<tr>
<td>↑ phonemic verbal fluency</td>
</tr>
<tr>
<td>↑ resistance to interference (Stroop)</td>
</tr>
<tr>
<td>Pramipexole:</td>
</tr>
<tr>
<td>↓ verbal short-term memory</td>
</tr>
<tr>
<td>↓ attention and set-shifting (trail making test and attentive matrices). (A similar trend was observed for levodopa in these tasks but without reaching statistical significance.)</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr20-2045125312470130">Cools <italic>et al</italic>. [2003]</xref></td>
<td rowspan="2">Levodopa</td>
<td rowspan="2">12 PD 24 HC</td>
<td>↑ Task-switching</td>
</tr>
<tr>
<td>↓ Decision making (increasing impulsivity)</td>
</tr>
<tr>
<td rowspan="4"><xref ref-type="bibr" rid="bibr27-2045125312470130">Costa <italic>et al</italic>. [2003]</xref></td>
<td rowspan="4">Levodopa Apomorphine</td>
<td rowspan="4">20 PD</td>
<td>Levodopa:</td>
</tr>
<tr>
<td>↑ visuospatial working memory (improving accuracy and reaction time)</td>
</tr>
<tr>
<td>Apomorphine:</td>
</tr>
<tr>
<td>↓ visuospatial working memory (worsening reaction time; any effect on accuracy)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr62-2045125312470130">Mollion <italic>et al</italic>. [2003]</xref></td>
<td>Levodopa</td>
<td>18 PD 9 HC</td>
<td>↑ Working memory (diminished time response)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr13-2045125312470130">Brusa <italic>et al</italic>. [2005]</xref></td>
<td>Levodopa Pergolide</td>
<td>20 PD</td>
<td>Any cognitive effect</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr18-2045125312470130">Cools <italic>et al</italic>. [2006]</xref></td>
<td>Levodopa Pramipexole Pergolide</td>
<td>20 PD</td>
<td>↓ Reversal learning (worse effect of pramipexole in comparison to levodopa)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr33-2045125312470130">Fera <italic>et al</italic>. [2007]</xref></td>
<td>Levodopa</td>
<td>12 PD</td>
<td>↑ Resistance to interference (accuracy in the Stroop task)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr5-2045125312470130">Beato <italic>et al</italic>. [2008]</xref></td>
<td>Levodopa</td>
<td>18 PD</td>
<td>↑Spatial working memory</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr25-2045125312470130">Costa <italic>et al</italic>. [2008]</xref></td>
<td>Levodopa</td>
<td>20 PD 15 HC</td>
<td>↑ Prospective memory</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr70-2045125312470130">Pascual-Sedano <italic>et al</italic>. [2008]</xref></td>
<td>Levodopa</td>
<td>14 PD</td>
<td>↑ Working memory with high cognitive load</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr26-2045125312470130">Costa <italic>et al</italic>. [2009]</xref></td>
<td>Pergolide pramipexole</td>
<td>19 de novo PD 13 HC</td>
<td>↑ Visuospatial and verbal working memory in patients with low ‘off’ therapy baseline performance</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr23-2045125312470130">Cools <italic>et al</italic>. [2010]</xref></td>
<td rowspan="2">Levodopa</td>
<td rowspan="2">15 PD 14 HC</td>
<td>↑ Working memory</td>
</tr>
<tr>
<td>↓ Distractor resistance</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr31-2045125312470130">Edelstyn <italic>et al</italic>. [2010]</xref></td>
<td>Levodopa</td>
<td>12 mild PD 11 moderate PD 21 HC</td>
<td>↓ Recollection of episodic details in a recognition task In moderate PD patients</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr44-2045125312470130">Hanna-Pladdy and Heilman, [2010]</xref></td>
<td>Levodopa</td>
<td>12 PD 12 HC</td>
<td>↑ Action planning in a figure replication tasks (increasing speed of figure completion)</td>
</tr>
<tr>
<td>Jananshahi <italic>et al</italic>. [2010]</td>
<td>Levodopa</td>
<td>11 PD 13 HC</td>
<td>↓ Probabilistic classification learning in the WPT</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr60-2045125312470130">Mattis <italic>et al</italic>. [2011]</xref></td>
<td>Levodopa</td>
<td>17 PD</td>
<td>↑ Verbal learning</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr30-2045125312470130">Drijgers <italic>et al</italic>. [2012]</xref></td>
<td>Pramipexole</td>
<td>23 agonist-naïve PD 23 HC</td>
<td>Any cognitive effect</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2045125312470130">
<p><italic>Legend</italic>: ↑, improved cognitive performance; ↓, worsened cognitive performance; HC, healthy controls; <italic>de novo</italic>, newly diagnosed drug-naïve; PD, Parkinson’s disease; WCST, Wisconsin Card Sorting Test; WPT, weather prediction task.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Results of these studies have to be evaluated considering the spatiotemporal progression of dopamine depletion within the striatum. In the early stages of PD the dopamine depletion is greatest (to a maximum of about 90%) in the most dorsolateral extent of the head of the caudate nucleus, producing a dysfunction of the dorsolateral frontostriatal circuit, while the orbital circuit is almost preserved; only in more advanced stages of the disease the orbital frontostriatal circuit is affected by dopamine depletion. This spatiotemporal difference in dopamine depletion at the striatal level explains why the effect of dopaminergic drugs is not linearly correlated with cognition.</p>
<p>One of the first studies on the effects of levodopa on cognitive functions of PD patients demonstrated the enhancement induced by levodopa on performances in executive tasks of verbal and visuospatial working memory and categorization (Wisconsin Card Sorting Test) [<xref ref-type="bibr" rid="bibr53-2045125312470130">Kulisevsky <italic>et al</italic>. 1996</xref>]. These preliminary findings were subsequently confirmed by a series of studies that adopted several executive tasks, most of all included in the Cambridge Neuropsychological Test Automated Battery, showing that the withdrawal of dopaminergic medication in early PD patients has a detrimental effect on set-switching and working memory [<xref ref-type="bibr" rid="bibr19-2045125312470130">Cools <italic>et al</italic>. 2001</xref>, <xref ref-type="bibr" rid="bibr21-2045125312470130">2002a</xref>, <xref ref-type="bibr" rid="bibr20-2045125312470130">2003</xref>, <xref ref-type="bibr" rid="bibr22-2045125312470130">2010</xref>], which are associated with the dorsolateral frontostriatal circuit, whereas it has a beneficial effect on probabilistic reversal learning, associated with the orbital frontostriatal circuit [<xref ref-type="bibr" rid="bibr24-2045125312470130">Cools <italic>et al</italic>. 2002b</xref>, <xref ref-type="bibr" rid="bibr17-2045125312470130">2006</xref>, <xref ref-type="bibr" rid="bibr22-2045125312470130">2007</xref>]. Because the effects of levodopa depend mainly on its ability to elevate dopamine levels in the striatum [<xref ref-type="bibr" rid="bibr59-2045125312470130">Maruyama <italic>et al</italic>. 1996</xref>], the observed different effects on set-shifting and working memory <italic>versus</italic> reversal learning are most likely due to effects of dopamine in the dorsal and the ventral striatum, respectively, which are known to be connected to different cortical areas via segregated frontostriatal circuits [<xref ref-type="bibr" rid="bibr18-2045125312470130">Cools <italic>et al</italic>. 2006</xref>]. This double dissociation is evident when directly comparing patients ‘on’ and ‘off’ medication and is in line with the ‘dopamine overdose hypothesis’, first formulated by Gotham and colleagues [<xref ref-type="bibr" rid="bibr38-2045125312470130">Gotham <italic>et al</italic>. 1986</xref>], which suggests that the administration of dopaminergic medication to PD patients may replete dopamine-depleted circuits, but overdose relatively intact ones. Indeed, other recent studies confirmed that in the early stages of PD, the treatment with levodopa has a beneficial effect on DLPFC-related executive functions, including attention, set-shifting, working memory and planning [<xref ref-type="bibr" rid="bibr5-2045125312470130">Beato <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr33-2045125312470130">Fera <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr44-2045125312470130">Hanna-Pladdy and Heilman, 2010</xref>; <xref ref-type="bibr" rid="bibr62-2045125312470130">Mollion <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr63-2045125312470130">Molloy <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr70-2045125312470130">Pascual-Sedano <italic>et al</italic>. 2008</xref>] but has a detrimental effect on OFC-related executive functions, that provide a reward-based control of behavior, as evidenced by poor performances in tasks of decision making under ambiguity and reversal learning [<xref ref-type="bibr" rid="bibr49-2045125312470130">Jahanshahi <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr79-2045125312470130">Rowe <italic>et al</italic>. 2008</xref>].</p>
<p>In advanced PD, when the dopamine depletion affects also the orbital frontostriatal circuit, levodopa is expected to have beneficial effects also on the executive functions related to this frontostriatal circuit; this prediction is actually not sustained by empirical evidence because no studies assessed OFC-related executive functions in advanced PD patients, probably due to the frequent association with dementia in these later stages, and since severe motor impairment often hampers the neuropsychological assessment and the identification of specific cognitive deficits in these patients [<xref ref-type="bibr" rid="bibr73-2045125312470130">Poletti and Bonuccelli, 2012</xref>].</p>
<p>As underlined at the beginning of this section, the majority of studies on the effects of dopaminergic drugs on the cognitive status of PD patients focused on executive prefrontal functions, while very few studies investigated other cognitive functions. The enhancement effect of levodopa involves not only functions that are influenced by executive functions [<xref ref-type="bibr" rid="bibr58-2045125312470130">Martin <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr87-2045125312470130">Vanderploeg <italic>et al</italic>. 1994</xref>], such as prospective memory and verbal learning [<xref ref-type="bibr" rid="bibr25-2045125312470130">Costa <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr60-2045125312470130">Mattis <italic>et al</italic>. 2011</xref>], but also other functions poorly influenced by executive functions, such as semantic priming [<xref ref-type="bibr" rid="bibr3-2045125312470130">Anqwin <italic>et al</italic>. 2009</xref>], i.e. the faster recognition of a target word when it is preceded by a related prime word compared with an unrelated word. Interestingly, a recent empirical trend highlighted the influence of the dopaminergic striatal system on the hippocampus and the related episodic memory system [<xref ref-type="bibr" rid="bibr64-2045125312470130">Morcom <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr84-2045125312470130">Shohamy and Adcock, 2010</xref>]; therefore, PD appears to be a good empirical model to be adopted in future studies to investigate the relationship between the dopaminergic system and different memory systems [<xref ref-type="bibr" rid="bibr31-2045125312470130">Edelstyn <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr34-2045125312470130">Foerde and Shohamy, 2011</xref>].</p>
<p>The majority of studies on cognitive effects of dopaminergic drugs used levodopa, providing a phasic stimulation; in recent years some studies have begun to investigate also the cognitive effects of dopamine agonists, providing tonic dopaminergic stimulation. A study found that pergolide, a D1/D2 agonist, had no cognitive effects (on episodic verbal memory and executive functions) on PD patients, similarly to levodopa [<xref ref-type="bibr" rid="bibr13-2045125312470130">Brusa <italic>et al</italic>. 2005</xref>]; the same research team reported that pramipexole, a D2/D3 agonist, produced a significant impairment of short-term verbal memory, attention and executive functions, while levodopa did not, in a group of early/mild PD patients [<xref ref-type="bibr" rid="bibr12-2045125312470130">Brusa <italic>et al</italic>. 2003</xref>]. Differently, a study reported that both pergolide and pramipexole improved performance accuracy on verbal and visuospatial working memory tasks in a sample of newly diagnosed drug-naïve PD patients with low baseline performance [<xref ref-type="bibr" rid="bibr26-2045125312470130">Costa <italic>et al</italic>. 2009</xref>]; finally, a recent study [<xref ref-type="bibr" rid="bibr30-2045125312470130">Drijgers <italic>et al</italic>. 2012</xref>] reported any acute cognitive effect of pramipexole in a sample of 23 pramipexole-naïve PD patients.</p>
<p>Other studies investigated the effects of apomorphine and levodopa on the performances of a group of PD patients in visual–spatial and visual–object working memory tasks, compared with performances during ‘off’ phase [<xref ref-type="bibr" rid="bibr27-2045125312470130">Costa <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr65-2045125312470130">Muller <italic>et al</italic>. 2002</xref>]: apomorphine worsened reaction times in both visual–spatial and visual–object working memory tasks, while levodopa improved accuracy and reaction times in both visual–spatial and visual–object tasks.</p>
</sec>
<sec id="section6-2045125312470130">
<title>Chronic dopaminergic stimulation</title>
<p>A different issue regards the chronic cognitive effect of dopaminergic drugs on PD patients. While negative effects of levodopa on motor functioning are well known (e.g. dyskinesia [<xref ref-type="bibr" rid="bibr72-2045125312470130">Poewe <italic>et al</italic>. 2010</xref>], it is unclear whether the prolonged chronic therapy with dopaminergic drugs, usually taken for many years, has beneficial (protective), neutral or detrimental effects on the cognitive status of PD patients. Indeed, the systematic review of literature found only three studies that investigated this issue (see <xref ref-type="table" rid="table2-2045125312470130">Table 2</xref>): one study [<xref ref-type="bibr" rid="bibr54-2045125312470130">Kulisevsky <italic>et al</italic>. 2000</xref>] followed 20 <italic>de novo</italic> PD patients for a period of 24 months of treatment with levodopa (10 patients) or pergolide (10 patients; to these patients levodopa was added after 6 months). Both treatments were associated with significant improvements in motor scores and in all cognitive tasks at the first follow up evaluation (until 18 months after the baseline assessment) but, while improvement in motor scores persisted, improvements in some tasks of executive functioning and of long-term memory were not sustained at the final 24-month examination. Another study [<xref ref-type="bibr" rid="bibr77-2045125312470130">Rektorova <italic>et al</italic>. 2005</xref>] assessed the cognitive functions of 41 PD patients in treatment with levodopa before and after 8 months of an add-on therapy with pramipexole or pergolide: any difference was found between cognitive performance at the baseline and after the therapy with dopamine agonists. A similar finding was reported by a study [<xref ref-type="bibr" rid="bibr78-2045125312470130">Relja and Klepac, 2006</xref>] that evaluated a sample of 16 medicated PD patients during 12 months of treatment: patients treated with levodopa alone and patients receiving pramipexole as add-on therapy to levodopa did not cognitively differ at the baseline and at the follow-up neuropsychological assessment.</p>
<table-wrap id="table2-2045125312470130" position="float">
<label>Table 2.</label>
<caption>
<p>Studies investigating chronic cognitive effects of levodopa and dopamine agonists in PD. The order is chronological.</p>
</caption>
<graphic alternate-form-of="table2-2045125312470130" xlink:href="10.1177_2045125312470130-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Temporal interval</th>
<th align="left">Dopaminergic drug</th>
<th align="left">Sample (<italic>n</italic>)</th>
<th align="left">Main effect of dopaminergic drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5"><xref ref-type="bibr" rid="bibr54-2045125312470130">Kulisevsky <italic>et al</italic>. [2000]</xref></td>
<td rowspan="5">3, 6, 12, 18, 24 months</td>
<td rowspan="5">Levodopa Pergolide (6 months in monotherapy, + levodopa thereafter)</td>
<td rowspan="5">20 <italic>de novo</italic> PD</td>
<td>Both levodopa and pergolide:</td>
</tr>
<tr>
<td>↑ verbal episodic memory (RAVLT) from 6 months to 12 months, then ↓ to basal level at 18 and 24 months</td>
</tr>
<tr>
<td>↑ visuospatial and visuoconstructive abilities and visual memory (RCFT) from 6 months to 12 months, then ↓ to basal level at 18 and 24 months</td>
</tr>
<tr>
<td>↑ semantic verbal fluency from 6 months to 12 months, then ↓ to basal level at 18 and 24 months</td>
</tr>
<tr>
<td>↑ phonemic verbal fluency from 6 months to 18 months, then ↓ to basal level at 24 months</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr77-2045125312470130">Rektorova <italic>et al</italic>. [2005]</xref></td>
<td>8 months</td>
<td>Levodopa+pramipexole Levodopa+pergolide</td>
<td>41 PD</td>
<td>Any cognitive effect; any cognitive difference between levodopa+pramipexole and levodopa+ pergolide</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr78-2045125312470130">Relja and Klepac [2006]</xref></td>
<td>12 months</td>
<td>Levodopa Levodopa+pramipexole</td>
<td>16 PD 8 HC</td>
<td>Any cognitive effect; any cognitive difference between levodopa and levodopa+pramipexole</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-2045125312470130">
<p><italic>Legend</italic>: ↑, improved cognitive performance; ↓, worsened cognitive performance; HC, healthy controls; <italic>de novo</italic>, newly diagnosed drug-naïve; PD, Parkinson’s disease; RAVLT, Rey auditory verbal learning task; RCFT, Rey complex figure test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>These findings preliminary showed that: (1) chronic dopaminergic stimulation at least do not have negative mid-term effects on cognitive functions of PD patients; (2) levodopa and dopamine agonists do not have differential mid-term effects on cognitive functions of PD patients. In these studies patients were followed only for brief periods (from 6 months to 2 years), while dopaminergic drugs may be taken by PD patients for many years: this suggests that the long-term effect of chronic dopaminergic stimulation with levodopa or dopamine agonists on cognitive functions of PD patients is actually almost unknown.</p>
</sec>
</sec>
<sec id="section7-2045125312470130" sec-type="discussion">
<title>Discussion</title>
<p>This article aimed at reviewing empirical evidence on the cognitive effects of dopaminergic drugs in PD. The study of cognition in patients with PD is of particular interest because the spatiotemporal progression of dopamine depletion during the course of the disease provides a special model for assessing dopaminergic effects on neural systems with differential baseline dopamine levels. The interaction between degrees of dopamine depletion (dorsolateral <italic>versus</italic> orbital frontostriatal circuits; left hemisphere <italic>versus</italic> right hemisphere) and different dopamine replacement therapies may produce different cognitive profiles at different stages of the disease: this complex clinical picture could partially explain why findings of studies on cognitive functions of PD patients are usually heterogeneous also within the same cognitive domain.</p>
<p>Considering different possibilities of empirical investigation of cognitive effects of dopaminergic drugs in PD in relation to drug (levodopa or dopamine agonist), temporal interval (acute or chronic) and cognitive domain, we found that empirical evidence is almost focused on acute effects of levodopa administration on prefrontal executive functions.</p>
<sec id="section8-2045125312470130">
<title>Acute cognitive effects: levodopa</title>
<p>Reviewed empirical findings are compatible with neuroanatomical and neurochemical models of dopaminergic frontostriatal systems and their cognitive functions [<xref ref-type="bibr" rid="bibr16-2045125312470130">Chudasama and Robbins, 2006</xref>; <xref ref-type="bibr" rid="bibr68-2045125312470130">Owen, 2004</xref>]. All of these models commonly propose that, in early PD patients, the withdrawal of dopaminergic medication has a detrimental effect on cognitive functions associated with the dorsolateral loop, and a beneficial effect on the cognitive functions associated with the orbital loop; this pattern has been recently confirmed and better specified by a study that matched behavioral performances of PD patients ‘on’ and ‘off’ dopaminergic drugs and fMRI findings in healthy subjects in a simple selection task [<xref ref-type="bibr" rid="bibr56-2045125312470130">MacDonald <italic>et al</italic>. 2011</xref>]. Findings confirmed that ventral striatum and the related orbital frontostriatal circuit is involved in learning new stimulus–stimulus associations and its functioning is impaired in early PD stages by dopaminergic drugs; on the other hand, dorsal striatum and the related dorsolateral frontostriatal circuit is involved in the assimilation of new and relevant information for the production of more accurate selections, for example shifting attention to more salient stimuli, and its functioning is enhanced in early PD stages by dopaminergic drugs.</p>
<p>This double dissociation involving cognitive effects of dopaminergic drugs is therefore evident when directly comparing patients ‘on’ and ‘off’ dopaminergic medication and was first suggested by the ‘<italic>dopamine overdose hypothesis</italic>’ [<xref ref-type="bibr" rid="bibr38-2045125312470130">Gotham <italic>et al</italic>. 1986</xref>, <xref ref-type="bibr" rid="bibr39-2045125312470130">1988</xref>], stating that the administration of dopaminergic medication to early PD patients may replete dopamine-depleted circuits (including the dorsal striatum), thus improving performances in tasks related to the dorsolateral loop while ‘overdosing’ relatively intact circuits (including the orbital loop). As levodopa mainly elevates dopamine levels in the striatum [<xref ref-type="bibr" rid="bibr46-2045125312470130">Hornykiewicz, 1974</xref>; <xref ref-type="bibr" rid="bibr59-2045125312470130">Maruyama <italic>et al</italic>. 1996</xref>], these differential effects are likely due to opposing effects of levodopa in the dorsal and the ventral striatum, which are connected to different cortical areas via segregated frontostriatal loops [<xref ref-type="bibr" rid="bibr2-2045125312470130">Alexander <italic>et al</italic>. 1986</xref>].</p>
<p>The <italic>neurocomputational model</italic> of frontostriatal circuitry functioning in PD [<xref ref-type="bibr" rid="bibr37-2045125312470130">Frank <italic>et al</italic>. 2004</xref>] proposed that basal ganglia modulate the selection of actions under consideration in the PFC. Two main projection pathways from the striatum travel up to the cortex through the thalamus via different basal ganglia output structures. The subthalamic nucleus provides a self-adaptive, dynamic control signal that temporarily prevents the execution of any response, depending on decision conflict [<xref ref-type="bibr" rid="bibr35-2045125312470130">Frank, 2006</xref>]. The direct frontostriatal ‘orbital’ pathway is excitatory and the indirect frontostriatal ‘orbital’ pathway is inhibitory. Transient changes in dopamine levels that occur during positive and negative feedback loops have opposite effects on the D1 and D2 (dopamine) receptors, which are relatively segregated in the direct and indirect pathways, respectively [<xref ref-type="bibr" rid="bibr45-2045125312470130">Hernandez-Lopez <italic>et al</italic>. 2000</xref>]. Dopamine bursts during positive reinforcement activate the direct pathway and deactivate the indirect pathway, driving learning so that reinforced responses are subsequently facilitated. Conversely, decreases in dopamine result in negative feedback, or deactivation, of the direct pathway and activation of the indirect pathway. Thus, unreinforced responses are subsequently suppressed or avoided. This model predicts a stronger processing of positive rewards in medicated PD patients, since levodopa increases dopaminergic bursts and facilitates an excitatory activity in the direct pathway of the cortico-striato-thalamo-cortical loops. Otherwise, medicated PD patients should show a decreased ability to learn through the mechanism of reward omission. This is because levodopa prevents dips in dopaminergic systems, which disturbs the inhibitory activity of the indirect pathway in the cortico-striato-thalamo-cortical loop. Unmedicated patients should show the opposite pattern, learning sufficiently from negative feedback to avoid harm, while showing impairment in learning from positive reinforcement. This neurocomputational model has been empirically confirmed by administrating a probabilistic selection task to PD patients ‘on’ and ‘off’ dopaminergic medication [<xref ref-type="bibr" rid="bibr36-2045125312470130">Frank <italic>et al</italic>. 2007</xref>]: levodopa altered the patients’ tendency to learn from positive versus negative outcomes, without modifying conflict-induced slowing.</p>
<p>The <italic>tonic/phasic model of dopamine system regulation</italic> [<xref ref-type="bibr" rid="bibr41-2045125312470130">Grace, 2000</xref>; <xref ref-type="bibr" rid="bibr40-2045125312470130">Goto and Grace, 2005</xref>] proposed that the nucleus accumbens (NAcc) is believed to regulate goal-directed behavior because it receives convergent synaptic inputs from limbic structures and the PFC. Thus, the NAcc is located such that contextual information from the hippocampus and emotional information from the amygdala, could be integrated with actions programmed in the PFC [<xref ref-type="bibr" rid="bibr41-2045125312470130">Grace, 2000</xref>]. Electrophysiological experiments in rats showed that tonic and phasic dopamine release selectively modulates hippocampal and prefrontal cortical inputs through the D1 and D2 receptors, respectively. In addition, D1 activation and D2 inactivation in the NAcc produces behaviorally selective effects (learning <italic>versus</italic> set-shifting of the response strategy) that correspond to specific afferents. These results suggest that the dynamics of dopamine release regulate the balance between the limbic and cortical drives through activation and inactivation of specific dopamine receptor subtypes in the NAcc, and this regulates goal-directed behavior [<xref ref-type="bibr" rid="bibr40-2045125312470130">Goto and Grace, 2005</xref>].</p>
<p>These results are also consistent with empirical results on the detrimental effects of dopaminergic medication on reversal learning in patients with mild PD [<xref ref-type="bibr" rid="bibr18-2045125312470130">Cools <italic>et al</italic>. 2006</xref>], as described in the <italic>inverted U-shape model</italic> of Cools [<xref ref-type="bibr" rid="bibr17-2045125312470130">Cools, 2006</xref>] describing differential effects of dopaminergic drugs on functions of the orbital and of the dorsolateral prefrontal circuits along the PD disease progression.</p>
<p>A subsequent fMRI study [<xref ref-type="bibr" rid="bibr22-2045125312470130">Cools <italic>et al</italic>. 2007</xref>] clarified the neural mechanism underlying this impaired reversal learning caused by dopaminergic therapy in PD patients: PD patients who were ‘on’ or ‘off’ levodopa medication had their brain activity measured by fMRI while performing a probabilistic reversal learning task able to activate the ventral striatum and the orbital frontostriatal circuit. fMRI data showed a role of the NAcc in the dopaminergic modulation of reversal learning in patients with mild PD. Reversal learning was accompanied by an increased NAcc activity only when patients were ‘off’ their dopaminergic therapy. Upon resuming therapy, reversal learning was disrupted due to changes in the functioning of the NAcc. Further studies are necessary to address the pharmacological mechanisms underlying the medication-induced reversal impairment; in particular, studies in patients with severe PD accompanied by a loss of dopamine in the NAcc, will reveal whether the levodopa-induced deficits in patients with mild PD depend on the level of dopamine depletion in the NAcc. Whereas other accounts of the medication-induced impairment do not require the NAcc to be intact [<xref ref-type="bibr" rid="bibr37-2045125312470130">Frank <italic>et al</italic>. 2004</xref>], it is possible that the impairment could be abolished during progression of the disease. Therefore, in an overdosed orbital loop, the dopaminergic replacement therapy prevents the dips in those dopaminergic systems that support the ‘no go’ learning through the indirect pathway of the cortico-striato-thalamo-cortical loop. This phenomenon likely causes dysfunctional reward processing, which impairs learning from reward omission [<xref ref-type="bibr" rid="bibr36-2045125312470130">Frank <italic>et al</italic>. 2007</xref>]. Moreover, considering that the phasic-acting levodopa needed to restore dopaminergic bursts effaces dopaminergic dips during reinforcement learning, while tonic-acting dopamine agonists should impair both dopaminergic bursts and dips, the question remains as to whether levodopa and dopamine agonists have different effects on reinforcement learning.</p>
</sec>
<sec id="section9-2045125312470130">
<title>Acute cognitive effects: dopamine agonists</title>
<p>Few studies were specifically designed to assess acute cognitive effects of dopamine agonists in comparison with levodopa and between different dopamine agonists. As regards pergolide and pramipexole, their positive effect on working memory performances of <italic>de novo</italic> PD patients [<xref ref-type="bibr" rid="bibr26-2045125312470130">Costa <italic>et al</italic>. 2009</xref>] is in line with the inverted U-shape curve model [<xref ref-type="bibr" rid="bibr17-2045125312470130">Cools, 2006</xref>], stating that dopaminergic stimulation in early disease stages replaces the functioning of the dorsolateral frontostriatal circuit, primary involved in working memory; indeed, dopamine agonists had a more beneficial effect in those patients with lower baseline performances, indirectly indicating the presence of a more severe nigrostriatal damage. As regards different findings between cognitive effects of pergolide (neutral) and pramipexole (detrimental) in early medicated patients [<xref ref-type="bibr" rid="bibr12-2045125312470130">Brusa <italic>et al</italic>. 2003</xref>, <xref ref-type="bibr" rid="bibr13-2045125312470130">2005</xref>], considering that patients had similar age and disease duration in the two studies (58 <italic>versus</italic> 57 years; 2.6 <italic>versus</italic> 2.5 years of disease duration), the different characteristics (respectively D1/D2 <italic>versus</italic> D2/D3 agonist) of these drugs probably may have played a role. Moreover, the longer mean disease duration (5 years) of patients evaluated by Drijgers and colleagues [<xref ref-type="bibr" rid="bibr30-2045125312470130">Drijgers <italic>et al</italic>. 2012</xref>], in comparison with previous studies, could partially explain the finding of a neutral effect of pramipexole.</p>
<p>Overall, it could be concluded that whereas the acute effects of levodopa on cognitive functions at different stages of PD seem to be established and well described by the inverted U-shape curve model [<xref ref-type="bibr" rid="bibr17-2045125312470130">Cools, 2006</xref>], no meaningful conclusions can be drawn at this time in relation to the acute effects of dopamine agonists on cognition, as compared with levodopa, and the differential effects of different dopamine agonists on cognition. However, dopaminergic receptors are differently represented in the human brain [<xref ref-type="bibr" rid="bibr9-2045125312470130">Bonuccelli <italic>et al</italic>. 2009</xref>], are differently involved by phasic and tonic stimulation [Deleu <italic>et al</italic>. 2012] and are differently involved in cognition [<xref ref-type="bibr" rid="bibr86-2045125312470130">Takahashi <italic>et al</italic>. 2012</xref>]; considering that different dopamine agonists have different effects on dopamine receptors, with ergolines (bromocriptine, pergolide, lisuride and cabergoline) stimulating D1 and D2 receptors and nonergolines (pramipexole, ropinirole and rotigotine) stimulating D2 and D3 receptors [<xref ref-type="bibr" rid="bibr9-2045125312470130">Bonuccelli <italic>et al</italic>. 2009</xref>] at least different categories of dopamine agonists (ergolines <italic>versus</italic> nonergolines, i.e. D1/D2 <italic>versus</italic> D2/D3 agonists) are deemed to have probably different cognitive effects on PD patients, that have to be investigated in future studies.</p>
</sec>
<sec id="section10-2045125312470130">
<title>Chronic cognitive effects</title>
<p>Whereas the acute effects of levodopa on prefrontal executive functions at different stages of PD, especially at early stages, seem to be established and well described by current models of dopaminergic systems, no meaningful conclusions can be drawn and further empirical research is needed in relation to the cognitive effects of prolonged dopaminergic therapies. This issue is of particular clinical interest considering that since the time of clinical diagnosis of PD many patients present a mild cognitive impairment: is this cognitive feature worsened or improved by the prolonged dopaminergic therapy? In addition to the potential risk of inducing dyskinesia and behavioral side effects such as impulse control disorders [<xref ref-type="bibr" rid="bibr89-2045125312470130">Weintraub <italic>et al</italic>. 2010</xref>], also cognitive effects of prolonged dopaminergic treatments should be taken into account by clinicians in order to anticipate or to delay their prescription to PD patients, possibly adopting other drugs with possible effects of neuroprotection and cognitive enhancement, as the selective monoamine oxidase type-B inhibitor rasagiline [<xref ref-type="bibr" rid="bibr32-2045125312470130">Elmer <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr43-2045125312470130">Hanagasi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr50-2045125312470130">Jenner and Langston, 2011</xref>].</p>
</sec>
<sec id="section11-2045125312470130">
<title>Future directions</title>
<p>In addition to the clinical issues delineated previously, other issues should be investigated in future studies.</p>
<p>First, although dopamine systems are mainly involved in prefrontal executive functions and the main cognitive effects of dopaminergic drugs are expected to involve them, other cognitive domains have to be investigated from this perspective even if cognitive effects are probably more subtle and difficult to be identified; for example, preliminary empirical evidence suggests that dopaminergic systems are involved, at least with a modulatory effect, in episodic memory [<xref ref-type="bibr" rid="bibr84-2045125312470130">Shohamy and Adcock, 2010</xref>], but any conclusion can be actually drawn. Also within the domain of prefrontal executive functions more studies are needed: indeed most studies focused on functions of the orbital and of the dorsolateral frontostriatal circuits, while functions of the ‘anterior cingulate’ frontostriatal circuit (including the anterior cingulated cortex [ACC], the striatum [ventromedial caudate nucleus, ventral putamen] the nucleus accumbens, the olfactory tubercle, the globus pallidus [rostromedial] and the thalamus) have been scarcely investigated in PD: this circuit has been involved in motivated behavior, considering that its damages clinically result in apathetic syndromes [<xref ref-type="bibr" rid="bibr8-2045125312470130">Bonelli and Cummings, 2007</xref>]. Apathy is a common neuropsychiatric feature also in PD patients [<xref ref-type="bibr" rid="bibr85-2045125312470130">Starkstein <italic>et al</italic>. 2009</xref>] and has been associated with cingulate anatomic reductions and functional deficits [<xref ref-type="bibr" rid="bibr6-2045125312470130">Benoit and Robert, 2011</xref>; <xref ref-type="bibr" rid="bibr52-2045125312470130">Kostic and Filippi, 2011</xref>] and with executive impairment [<xref ref-type="bibr" rid="bibr74-2045125312470130">Poletti <italic>et al</italic>. 2012a</xref>], but the role of nigrostriatal dopaminergic deficit on apathy in PD and the potential role played by dopaminergic drugs are actually almost unknown and deserve further empirical investigation.</p>
<p>Second, in addition to the main dopaminergic dysfunction, other neurotransmitters are dysfunctional with different degrees in PD, including acetylcholine, serotonin and norepinephrine [<xref ref-type="bibr" rid="bibr4-2045125312470130">Baloyannis <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr7-2045125312470130">Bohnen <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr42-2045125312470130">Guttman <italic>et al</italic>. 2007</xref>], although their role in cognitive dysfunction is partially unknown [<xref ref-type="bibr" rid="bibr14-2045125312470130">Calabresi <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr57-2045125312470130">Marsh <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr82-2045125312470130">Scholtissen <italic>et al</italic>. 2006</xref>] and deserves further empirical investigation.</p>
</sec></sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Ubaldo Bonuccelli has been on advisory boards for GlaxoSmithKline, Lundbeck, Novartis and UCB, received honoraria for speeches at meetings from Boehringer Ingelheim, GlaxoSmithKline, Novartis, grants from the Regione Toscana Health Authority and intellectual property rights from Sperling and Kupfer for a book authorship. Michele Poletti has no conflicts of interest to declare.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aarsland</surname><given-names>D.</given-names></name>
<name><surname>Anderson</surname><given-names>K.</given-names></name>
<name><surname>Larsen</surname><given-names>J.</given-names></name>
<name><surname>Lolk</surname><given-names>A.</given-names></name>
<name><surname>Kragh-Sorensen</surname><given-names>P.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Prevalence and characteristics of dementia in Parkinson disease. A 8 year prospective study</article-title>. <source>Arch Neurol</source> <volume>60</volume>: <fpage>387</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr2-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>G.</given-names></name>
<name><surname>Delong</surname><given-names>M.</given-names></name>
<name><surname>Strick</surname><given-names>P.</given-names></name>
</person-group> (<year>1986</year>) <article-title>Parallel organisation of functionally segregated circuits linking basal ganglia and cortex</article-title>. <source>Ann Rev Neurosci</source> <volume>9</volume>: <fpage>357</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr3-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anqwin</surname><given-names>A.</given-names></name>
<name><surname>Arnott</surname><given-names>W.</given-names></name>
<name><surname>Copland</surname><given-names>D.</given-names></name>
<name><surname>Haire</surname><given-names>M.</given-names></name>
<name><surname>Murdoch</surname><given-names>B.</given-names></name>
<name><surname>Silburn</surname><given-names>P.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Semantic activation in Parkinson’s disease patients on and off levodopa</article-title>. <source>Cortex</source> <volume>45</volume>: <fpage>950</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr4-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baloyannis</surname><given-names>S.</given-names></name>
<name><surname>Costa</surname><given-names>V.</given-names></name>
<name><surname>Baloyannis</surname><given-names>I.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Morphological alterations of the synapses in the locus ceruleus in Parkinson’s disease</article-title>. <source>J Neurol Sci</source> <volume>248</volume>: <fpage>35</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr5-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beato</surname><given-names>R.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
<name><surname>Pillon</surname><given-names>B.</given-names></name>
<name><surname>du Montcel</surname><given-names>S.</given-names></name>
<name><surname>Deweer</surname><given-names>B.</given-names></name>
<name><surname>Bonnet</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Working memory in Parkinson’s disease patients: clinical features and response to levodopa</article-title>. <source>Arq Neuropsyquiatr</source> <volume>66</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr6-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benoit</surname><given-names>M.</given-names></name>
<name><surname>Robert</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Imaging correlates of apathy and depression in Parkinson’s disease</article-title>. <source>J Neurol Sci</source> <volume>310</volume>: <fpage>58</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr7-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bohnen</surname><given-names>N.</given-names></name>
<name><surname>Kaufer</surname><given-names>D.</given-names></name>
<name><surname>Hendrickson</surname><given-names>R.</given-names></name>
<name><surname>Ivanco</surname><given-names>L.</given-names></name>
<name><surname>Lopresti</surname><given-names>B.</given-names></name>
<name><surname>Costantine</surname><given-names>G.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementias</article-title>. <source>J Neurol</source> <volume>253</volume>: <fpage>242</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr8-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonelli</surname><given-names>R.</given-names></name>
<name><surname>Cummings</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Frontal-subcortical circuitry and behavior</article-title>. <source>Dialogues Clin Neurosci</source> <volume>9</volume>: <fpage>141</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr9-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
<name><surname>Del Dotto</surname><given-names>P.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Role of dopamine receptor agonists in the treatment of early Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source> <volume>15</volume>: <fpage>S44</fpage>–<lpage>S53</lpage>.</citation>
</ref>
<ref id="bibr10-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
<name><surname>Pavese</surname><given-names>N.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Dopamine agonists in the treatment of Parkinson’s disease</article-title>. <source>Expert Rev Neurother</source> <volume>6</volume>: <fpage>81</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr11-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braak</surname><given-names>H.</given-names></name>
<name><surname>Del Tredici</surname><given-names>K.</given-names></name>
<name><surname>Rub</surname><given-names>U.</given-names></name>
<name><surname>de Vos</surname><given-names>R.</given-names></name>
<name><surname>Jansen Steur</surname><given-names>E.</given-names></name>
<name><surname>Braak</surname><given-names>E.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Staging of brain pathology related to sporadic Parkinson’s disease</article-title>. <source>Neurobiol Aging</source> <volume>24</volume>: <fpage>197</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr12-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brusa</surname><given-names>L.</given-names></name>
<name><surname>Bassi</surname><given-names>A.</given-names></name>
<name><surname>Stefani</surname><given-names>A.</given-names></name>
<name><surname>Pierantozzi</surname><given-names>M.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Caramia</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>Pramipexole in comparison to l-dopa: a neuropsychological study</article-title>. <source>J Neural Transm</source> <volume>110</volume>: <fpage>373</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr13-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brusa</surname><given-names>L.</given-names></name>
<name><surname>Tiraboschi</surname><given-names>P.</given-names></name>
<name><surname>Koch</surname><given-names>G.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Pierantozzi</surname><given-names>M.</given-names></name>
<name><surname>Ruggieri</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Pergolide effect on cognitive functions in early mild Parkinson’s disease</article-title>. <source>J Neural Transm</source> <volume>112</volume>: <fpage>231</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr14-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabresi</surname><given-names>P.</given-names></name>
<name><surname>Picconi</surname><given-names>B.</given-names></name>
<name><surname>Parnetti</surname><given-names>L.</given-names></name>
<name><surname>Di Filippo</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine-acetylcholine synaptic balance</article-title>. <source>Lancet Neurol</source> <volume>5</volume>: <fpage>974</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr15-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaudhury</surname><given-names>K.</given-names></name>
<name><surname>Healy</surname><given-names>D.</given-names></name>
<name><surname>Schapira</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Non motor symptoms of Parkinson’s disease: diagnosis and management</article-title>. <source>Lancet Neurol</source> <volume>5</volume>: <fpage>235</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr16-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chudasama</surname><given-names>Y.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans</article-title>. <source>Biol Psychol</source> <volume>73</volume>: <fpage>19</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr17-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease</article-title>. <source>Neurosci Biobehav Rev</source> <volume>30</volume>: <fpage>1</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr18-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Altamirano</surname><given-names>L.</given-names></name>
<name><surname>D’Esposito</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Reversal learning in Parkinson’s disease depends of medication status and outcome valence</article-title>. <source>Neuropsychologia</source> <volume>44</volume>: <fpage>1663</fpage>–<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr19-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Barker</surname><given-names>R.</given-names></name>
<name><surname>Sahakian</surname><given-names>B.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands</article-title>. <source>Cereb Cortex</source> <volume>11</volume>: <fpage>1136</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr20-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Barker</surname><given-names>R.</given-names></name>
<name><surname>Sahakian</surname><given-names>B.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
</person-group> (<year>2003</year>) <article-title>L-dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease</article-title>. <source>Neuropsychologia</source> <volume>41</volume>: <fpage>1431</fpage>–<lpage>1441</lpage>.</citation>
</ref>
<ref id="bibr21-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Clark</surname><given-names>L.</given-names></name>
<name><surname>Owen</surname><given-names>A.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
</person-group> (<year>2002a</year>) <article-title>Defining the neural mechanism of probabilistic reversal learning using event-related functional magnetic resonance imaging</article-title>. <source>J Neurosci</source> <volume>22</volume>: <fpage>4583</fpage>–<lpage>4587</lpage>.</citation>
</ref>
<ref id="bibr22-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Lewis</surname><given-names>S.</given-names></name>
<name><surname>Clark</surname><given-names>L.</given-names></name>
<name><surname>Barker</surname><given-names>R.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease</article-title>. <source>Neuropsychopharmachology</source> <volume>32</volume>: <fpage>180</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr23-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Myakawa</surname><given-names>A.</given-names></name>
<name><surname>Sheridan</surname><given-names>M.</given-names></name>
<name><surname>D’Esposito</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Enhanced frontal function in Parkinson’s disease</article-title>. <source>Brain</source> <volume>133</volume>: <fpage>225</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr24-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cools</surname><given-names>R.</given-names></name>
<name><surname>Stefanova</surname><given-names>E.</given-names></name>
<name><surname>Barker</surname><given-names>R.</given-names></name>
<name><surname>Robbins</surname><given-names>T.</given-names></name>
<name><surname>Owen</surname><given-names>A.</given-names></name>
</person-group> (<year>2002b</year>) <article-title>Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET</article-title>. <source>Brain</source> <volume>125</volume>: <fpage>584</fpage>–<lpage>594</lpage>.</citation>
</ref>
<ref id="bibr25-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Brusa</surname><given-names>L.</given-names></name>
<name><surname>Caltagirone</surname><given-names>C.</given-names></name>
<name><surname>Gatto</surname><given-names>I.</given-names></name>
<name><surname>Carlesimo</surname><given-names>G.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Levodopa improves time-based prospective memory in Parkinson’s disease</article-title>. <source>J Int Neuropsychol Soc</source> <volume>14</volume>: <fpage>601</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr26-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Dell’Agnello</surname><given-names>G.</given-names></name>
<name><surname>Caltagirone</surname><given-names>C.</given-names></name>
<name><surname>Carlesimo</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory</article-title>. <source>Neuropsychologia</source> <volume>47</volume>: <fpage>1374</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr27-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.</given-names></name>
<name><surname>Peppe</surname><given-names>A.</given-names></name>
<name><surname>Dell’Agnello</surname><given-names>G.</given-names></name>
<name><surname>Carlesimo</surname><given-names>G.</given-names></name>
<name><surname>Murri</surname><given-names>L.</given-names></name>
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>Dopaminergic modulation of visuospatial working memory in Parkinson’s disease</article-title>. <source>Dementia Geriatr Cogn Disord</source> <volume>15</volume>: <fpage>55</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr28-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deleu</surname><given-names>D.</given-names></name>
<name><surname>Northway</surname><given-names>M.G.</given-names></name>
<name><surname>Hanssens</surname><given-names>Y.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Clinical pharmacokinetic and pharma-codynamic properties of drugs used in the treatment of Parkinson’s disease</article-title>. <source>Clin Pharmacokinet</source> <volume>41</volume>: <fpage>261</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr29-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Domellof</surname><given-names>M.</given-names></name>
<name><surname>Elgh</surname><given-names>E.</given-names></name>
<name><surname>Forsgren</surname><given-names>L.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The relation between cognition and motor dysfunction in drug-naïve newly diagnosed patients with Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>2183</fpage>–<lpage>2189</lpage>.</citation>
</ref>
<ref id="bibr30-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drijgers</surname><given-names>R.</given-names></name>
<name><surname>Verhey</surname><given-names>F.</given-names></name>
<name><surname>Tissingh</surname><given-names>G.</given-names></name>
<name><surname>van Domburg</surname><given-names>P.</given-names></name>
<name><surname>Aalten</surname><given-names>P.</given-names></name>
<name><surname>Leentjens</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The role of the dopaminergic system in mood, motivation and cognition in Parkinson’s disease: a double-blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate</article-title>. <source>J Neurol Sci</source> <volume>320</volume>: <fpage>121</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr31-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edelstyn</surname><given-names>N.</given-names></name>
<name><surname>Shepherd</surname><given-names>T.</given-names></name>
<name><surname>Mayes</surname><given-names>A.</given-names></name>
<name><surname>Sherman</surname><given-names>S.</given-names></name>
<name><surname>Ellis</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson’s</article-title>. <source>Neuropsychologia</source> <volume>48</volume>: <fpage>1367</fpage>–<lpage>1375</lpage>.</citation>
</ref>
<ref id="bibr32-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elmer</surname><given-names>L.</given-names></name>
<name><surname>Schwid</surname><given-names>S.</given-names></name>
<name><surname>Eberly</surname><given-names>S.</given-names></name>
<name><surname>Goetz</surname><given-names>C.</given-names></name>
<name><surname>Fahn</surname><given-names>S.</given-names></name>
<name><surname>Kieburtz</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms</article-title>. <source>J Neurol Sci</source> <volume>248</volume>: <fpage>78</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr33-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fera</surname><given-names>F.</given-names></name>
<name><surname>Nicoletti</surname><given-names>G.</given-names></name>
<name><surname>Cerasa</surname><given-names>A.</given-names></name>
<name><surname>Romeo</surname><given-names>N.</given-names></name>
<name><surname>Gallo</surname><given-names>O.</given-names></name>
<name><surname>Gioia</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson’s disease</article-title>. <source>Brain Res Bull</source> <volume>74</volume>: <fpage>75</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr34-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Foerde</surname><given-names>K.</given-names></name>
<name><surname>Shohamy</surname><given-names>D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Feedback timing modulates brain systems for learning in humans</article-title>. <source>J Neurosci</source> <volume>31</volume>: <fpage>13157</fpage>–<lpage>13166</lpage>.</citation>
</ref>
<ref id="bibr35-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frank</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Hold your horses: a dynamic neurocomputational role of the subthalamic nucleus in decision making</article-title>. <source>Neur Netw</source> <volume>19</volume>: <fpage>1120</fpage>–<lpage>1136</lpage>.</citation>
</ref>
<ref id="bibr36-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frank</surname><given-names>M.</given-names></name>
<name><surname>Samanta</surname><given-names>J.</given-names></name>
<name><surname>Moustafa</surname><given-names>A.</given-names></name>
<name><surname>Sherman</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Hold your horses: impulsivity, deep brain stimulation and medication in parkinsonism</article-title>. <source>Science</source> <volume>318</volume>: <fpage>1309</fpage>–<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr37-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frank</surname><given-names>M.</given-names></name>
<name><surname>Seeberger</surname><given-names>L.</given-names></name>
<name><surname>O’Reilly</surname><given-names>R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>By carrot or by stick: cognitive reinforcement learning in parkinsonism</article-title>. <source>Science</source> <volume>306</volume>: <fpage>1940</fpage>–<lpage>1943</lpage>.</citation>
</ref>
<ref id="bibr38-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotham</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Marsden</surname><given-names>C.</given-names></name>
</person-group> (<year>1986</year>) <article-title>Levodopa treatment may benefit or impair frontal function in Parkinson’s disease</article-title>. <source>Lancet</source> <volume>2</volume>: <fpage>970</fpage>–<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr39-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gotham</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Marsden</surname><given-names>C.D.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Frontal cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa</article-title>. <source>Brain</source> <volume>111</volume>: <fpage>299</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr40-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goto</surname><given-names>Y.</given-names></name>
<name><surname>Grace</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behaviour</article-title>. <source>Nat Neurosci</source> <volume>8</volume>: <fpage>805</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr41-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grace</surname><given-names>A.</given-names></name>
</person-group> (<year>2000</year>) <article-title>The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving</article-title>. <source>Addiction</source> <volume>95</volume>(<supplement>Suppl. 2</supplement>): <fpage>S119</fpage>–<lpage>S128</lpage>.</citation>
</ref>
<ref id="bibr42-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guttman</surname><given-names>M.</given-names></name>
<name><surname>Boileau</surname><given-names>I.</given-names></name>
<name><surname>Warsh</surname><given-names>J.</given-names></name>
<name><surname>Saint-Cyr</surname><given-names>J.</given-names></name>
<name><surname>Ginovart</surname><given-names>N.</given-names></name>
<name><surname>McCluskey</surname><given-names>T.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Brain serotonin transporter binding in nondepressed patients with Parkinson’s disease</article-title>. <source>Eur J Neurol</source> <volume>14</volume>: <fpage>523</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr43-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanagasi</surname><given-names>H.</given-names></name>
<name><surname>Gurvit</surname><given-names>H.</given-names></name>
<name><surname>Unsalan</surname><given-names>P.</given-names></name>
<name><surname>Horozoglu</surname><given-names>H.</given-names></name>
<name><surname>Tuncer</surname><given-names>M.</given-names></name>
<name><surname>Feyzioglu</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>1851</fpage>–<lpage>1858</lpage>.</citation>
</ref>
<ref id="bibr44-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanna-Pladdy</surname><given-names>B.</given-names></name>
<name><surname>Heilman</surname><given-names>K.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Dopaminergic modulation of the planning phase of skill acquisition in Parkinson’s disease</article-title>. <source>Neurocase</source> <volume>16</volume>: <fpage>182</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr45-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hernandez-Lopez</surname><given-names>S.</given-names></name>
<name><surname>Tkatch</surname><given-names>T.</given-names></name>
<name><surname>Perez-Garci</surname><given-names>E.</given-names></name>
<name><surname>Galarraga</surname><given-names>E.</given-names></name>
<name><surname>Bargas</surname><given-names>J.</given-names></name>
<name><surname>Hamm</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC (Beta)1-IP3 calcineurin signalling cascade</article-title>. <source>J Neurosci</source> <volume>20</volume>: <fpage>8987</fpage>–<lpage>8995</lpage>.</citation>
</ref>
<ref id="bibr46-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hornykiewicz</surname><given-names>O.</given-names></name>
</person-group> (<year>1974</year>) <article-title>The mechanism of action of l-dopa in Parkinson’s disease</article-title>. <source>Life Sci</source> <volume>15</volume>: <fpage>1249</fpage>–<lpage>1259</lpage>.</citation>
</ref>
<ref id="bibr47-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hosokai</surname><given-names>Y.</given-names></name>
<name><surname>Nishio</surname><given-names>Y.</given-names></name>
<name><surname>Hirayama</surname><given-names>K.</given-names></name>
<name><surname>Takeda</surname><given-names>A.</given-names></name>
<name><surname>Ishioka</surname><given-names>T.</given-names></name>
<name><surname>Sawada</surname><given-names>Y.</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Distinct patterns of cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment</article-title>. <source>Mov Disord</source> <volume>23</volume>: <fpage>854</fpage>–<lpage>862</lpage>.</citation>
</ref>
<ref id="bibr48-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>A.</given-names></name>
<name><surname>Daniel</surname><given-names>S.</given-names></name>
<name><surname>Kilford</surname><given-names>L.</given-names></name>
<name><surname>Lees</surname><given-names>A.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>155</volume>: <fpage>181</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr49-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jahanshahi</surname><given-names>M.</given-names></name>
<name><surname>Wilkinson</surname><given-names>L.</given-names></name>
<name><surname>Gahir</surname><given-names>H.</given-names></name>
<name><surname>Dharmarinda</surname><given-names>A.</given-names></name>
<name><surname>Lagnado</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Medication impairs probabilistic classification learning in Parkinson’s disease</article-title>. <source>Neuropsychologia</source> <volume>48</volume>: <fpage>1096</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr50-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jenner</surname><given-names>P.</given-names></name>
<name><surname>Langston</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline</article-title>. <source>Mov Disord</source> <volume>26</volume>: <fpage>2316</fpage>–<lpage>2323</lpage>.</citation>
</ref>
<ref id="bibr51-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kish</surname><given-names>S.</given-names></name>
<name><surname>Shannak</surname><given-names>K.</given-names></name>
<name><surname>Hornykiewicz</surname><given-names>O.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease</article-title>. <source>N Engl J Med</source> <volume>318</volume>: <fpage>876</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr52-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kostic</surname><given-names>V.</given-names></name>
<name><surname>Filippi</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Neuroanatomical correlates of depression and apathy in Parkinson’s disease: magnetic resonance imaging studies</article-title>. <source>J Neurol Sci</source> <volume>310</volume>: <fpage>61</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr53-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
<name><surname>Avila</surname><given-names>A.</given-names></name>
<name><surname>Barbanoj</surname><given-names>M.</given-names></name>
<name><surname>Antonijan</surname><given-names>R.</given-names></name>
<name><surname>Berthier</surname><given-names>M.</given-names></name>
<name><surname>Gironell</surname><given-names>A.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels</article-title>. <source>Brain</source> <volume>119</volume>: <fpage>2121</fpage>–<lpage>2132</lpage>.</citation>
</ref>
<ref id="bibr54-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
<name><surname>Garcia-Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Berthier</surname><given-names>M.</given-names></name>
<name><surname>Barbanoj</surname><given-names>M.</given-names></name>
<name><surname>Pascual-Sedano</surname><given-names>B.</given-names></name>
<name><surname>Gironell</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients</article-title>. <source>Mov Disord</source> <volume>15</volume>: <fpage>613</fpage>–<lpage>626</lpage>.</citation>
</ref>
<ref id="bibr55-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyoo</surname><given-names>Ch.</given-names></name>
<name><surname>Jeong</surname><given-names>Y.</given-names></name>
<name><surname>Ryu</surname><given-names>Y.</given-names></name>
<name><surname>Rinne</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment</article-title>. <source>Eur J Neurol</source> <volume>64</volume>: <fpage>65</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr56-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacDonald</surname><given-names>P.</given-names></name>
<name><surname>MacDonald</surname><given-names>A.</given-names></name>
<name><surname>Seergobin</surname><given-names>K.</given-names></name>
<name><surname>Tamjeedi</surname><given-names>R.</given-names></name>
<name><surname>Ganjavi</surname><given-names>H.</given-names></name>
<name><surname>Provost</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional fMRI</article-title>. <source>Brain</source> <volume>134</volume>: <fpage>1447</fpage>–<lpage>1463</lpage>.</citation>
</ref>
<ref id="bibr57-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marsh</surname><given-names>L.</given-names></name>
<name><surname>Biglan</surname><given-names>K.</given-names></name>
<name><surname>Gerstenhaber</surname><given-names>M.</given-names></name>
<name><surname>Williams</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>277</fpage>–<lpage>287</lpage></citation>
</ref>
<ref id="bibr58-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>M.</given-names></name>
<name><surname>Kliegel</surname><given-names>M.</given-names></name>
<name><surname>McDaniel</surname><given-names>M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>The involvement of executive functions in prospective memory performance of adults</article-title>. <source>Int J Psychol</source> <volume>38</volume>: <fpage>195</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr59-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maruyama</surname><given-names>W.</given-names></name>
<name><surname>Naoi</surname><given-names>M.</given-names></name>
<name><surname>Narabayashi</surname><given-names>H.</given-names></name>
</person-group> (<year>1996</year>) <article-title>The metabolism of L-Dopa and L-threo-3, 4-dihydroxyphreylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients</article-title>. <source>J Neurol Sci</source> <volume>139</volume>: <fpage>141</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr60-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mattis</surname><given-names>P.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Eidelberg</surname><given-names>D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Networks correlates of the cognitive response to levodopa in Parkinson disease</article-title>. <source>Neurology</source> <volume>77</volume>: <fpage>858</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr61-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyake</surname><given-names>A.</given-names></name>
<name><surname>Friedman</surname><given-names>N.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The nature and organization of individual differences in executive functions: four general conclusions</article-title>. <source>Curr Dir Psychol Sci</source> <volume>21</volume>: <fpage>8</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr62-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mollion</surname><given-names>H.</given-names></name>
<name><surname>Ventre-Dominey</surname><given-names>J.</given-names></name>
<name><surname>Dominey</surname><given-names>P.</given-names></name>
<name><surname>Broussolle</surname><given-names>E.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson’s disease</article-title>. <source>Neuropsychologia</source> <volume>41</volume>: <fpage>1442</fpage>–<lpage>1451</lpage>.</citation>
</ref>
<ref id="bibr63-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Molloy</surname><given-names>S.</given-names></name>
<name><surname>Rowan</surname><given-names>E.</given-names></name>
<name><surname>O’Brien</surname><given-names>J.</given-names></name>
<name><surname>McKeith</surname><given-names>I.</given-names></name>
<name><surname>Wesnes</surname><given-names>K.</given-names></name>
<name><surname>Burn</surname><given-names>D.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>77</volume>: <fpage>1323</fpage>–<lpage>1328</lpage>.</citation>
</ref>
<ref id="bibr64-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morcom</surname><given-names>A.</given-names></name>
<name><surname>Bullmore</surname><given-names>E.</given-names></name>
<name><surname>Huppert</surname><given-names>F.</given-names></name>
<name><surname>Lennox</surname><given-names>B.</given-names></name>
<name><surname>Praseedom</surname><given-names>A.</given-names></name>
<name><surname>Linnington</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Memory encoding and dopamine in the aging brain: a psychopharmacological neuroimaging study</article-title>. <source>Cereb Cortex</source> <volume>20</volume>: <fpage>743</fpage>–<lpage>757</lpage>.</citation>
</ref>
<ref id="bibr65-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>T.</given-names></name>
<name><surname>Benz</surname><given-names>S.</given-names></name>
<name><surname>Przuntek</surname><given-names>H.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Apomorphine delays simple reaction times in Parkinsonian patients</article-title>. <source>Parkinsonism Relat Disord</source> <volume>8</volume>: <fpage>357</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr66-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muslimovic</surname><given-names>D.</given-names></name>
<name><surname>Post</surname><given-names>B.</given-names></name>
<name><surname>Speelman</surname><given-names>J.</given-names></name>
<name><surname>Schmand</surname><given-names>B.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cognitive profile of patients with newly diagnosed Parkinson disease</article-title>. <source>Neurology</source> <volume>65</volume>: <fpage>1239</fpage>–<lpage>1245</lpage>.</citation>
</ref>
<ref id="bibr67-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nobili</surname><given-names>F.</given-names></name>
<name><surname>Arnaldi</surname><given-names>D.</given-names></name>
<name><surname>Campus</surname><given-names>C.</given-names></name>
<name><surname>Ferrara</surname><given-names>M.</given-names></name>
<name><surname>De Carli</surname><given-names>F.</given-names></name>
<name><surname>Brugnolo</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source> <volume>38</volume>: <fpage>2209</fpage>–<lpage>2218</lpage>.</citation>
</ref>
<ref id="bibr68-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Owen</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry</article-title>. <source>Neuroscientist</source> <volume>10</volume>: <fpage>525</fpage>–<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr69-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pappatà</surname><given-names>S.</given-names></name>
<name><surname>Santangelo</surname><given-names>G.</given-names></name>
<name><surname>Aarsland</surname><given-names>D.</given-names></name>
<name><surname>Vicidomini</surname><given-names>C.</given-names></name>
<name><surname>Longo</surname><given-names>K.</given-names></name>
<name><surname>Bronnick</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Mild cognitive impairment in drug-naïve patients with PD is associated with cerebral hypometabolism</article-title>. <source>Neurology</source> <volume>77</volume>: <fpage>1357</fpage>–<lpage>1362</lpage>.</citation>
</ref>
<ref id="bibr70-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pascual-Sedano</surname><given-names>B.</given-names></name>
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
<name><surname>Barbanoj</surname><given-names>M.</given-names></name>
<name><surname>Garcia-Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Campolongo</surname><given-names>A.</given-names></name>
<name><surname>Gironell</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Levodopa and executive performance in Parkinson’s disease: a randomized study</article-title>. <source>J Int Neuropsychol Soc</source> <volume>14</volume>: <fpage>832</fpage>–<lpage>841</lpage>.</citation>
</ref>
<ref id="bibr71-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perachon</surname><given-names>S.</given-names></name>
<name><surname>Schwartz</surname><given-names>J.</given-names></name>
<name><surname>Sokoloff</surname><given-names>P.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors</article-title>. <source>Eur J Pharmacol</source> <volume>366</volume>: <fpage>293</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr72-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poewe</surname><given-names>W.</given-names></name>
<name><surname>Antonini</surname><given-names>A.</given-names></name>
<name><surname>Zijlmans</surname><given-names>J.</given-names></name>
<name><surname>Burkhard</surname><given-names>P.</given-names></name>
<name><surname>Vingerhoets</surname><given-names>F.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Levodopa in the treatment of Parkinson’s disease: an old drug still going strong</article-title>. <source>Clin Interv Aging</source> <volume>7</volume>: <fpage>229</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr73-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poletti</surname><given-names>M.</given-names></name>
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: Neuropsychological evidence</article-title>. <source>Brain Cogn</source> <volume>79</volume>: <fpage>23</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr74-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poletti</surname><given-names>M.</given-names></name>
<name><surname>De Rosa</surname><given-names>A.</given-names></name>
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
</person-group> (<year>2012a</year>) <article-title>Affective symptoms and cognitive functions in Parkinson’s disease</article-title>. <source>J Neurol Sci</source> <volume>317</volume>: <fpage>97</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr75-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poletti</surname><given-names>M.</given-names></name>
<name><surname>Frosini</surname><given-names>D.</given-names></name>
<name><surname>Lucetti</surname><given-names>D.</given-names></name>
<name><surname>Del Dotto</surname><given-names>P.</given-names></name>
<name><surname>Ceravolo</surname><given-names>R.</given-names></name>
<name><surname>Bonuccelli</surname><given-names>U.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Decision making in de novo Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>25</volume>: <fpage>1432</fpage>–<lpage>1436</lpage>.</citation>
</ref>
<ref id="bibr76-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poletti</surname><given-names>M.</given-names></name>
<name><surname>Frosini</surname><given-names>D.</given-names></name>
<name><surname>Pagni</surname><given-names>C.</given-names></name>
<name><surname>Baldacci</surname><given-names>F.</given-names></name>
<name><surname>Nicoletti</surname><given-names>V.</given-names></name>
<name><surname>Tognoni</surname><given-names>G.</given-names></name>
<etal/></person-group>. (<year>2012b</year>) <article-title>Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naïve patients with Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>83</volume>: <fpage>601</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr77-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rektorova</surname><given-names>I.</given-names></name>
<name><surname>Rektor</surname><given-names>I.</given-names></name>
<name><surname>Bares</surname><given-names>M.</given-names></name>
<name><surname>Dostal</surname><given-names>V.</given-names></name>
<name><surname>Ehler</surname><given-names>E.</given-names></name>
<name><surname>Fanrdlova</surname><given-names>Z.</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Cognitive performance in people with Parkinson’s disease and mild and moderate depression: effects of dopamine agonists in add-on to L-dopa therapy</article-title>. <source>Eur J Neurol</source> <volume>12</volume>: <fpage>9</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr78-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Relja</surname><given-names>M.</given-names></name>
<name><surname>Klepac</surname><given-names>N.</given-names></name>
</person-group> (<year>2006</year>) <article-title>A dopamine agonist, pramipexole, and cognitive functions in Parkinson’s disease</article-title>. <source>J Neurol Sci</source> <volume>248</volume>: <fpage>251</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr79-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowe</surname><given-names>J.</given-names></name>
<name><surname>Hughes</surname><given-names>L.</given-names></name>
<name><surname>Ghosh</surname><given-names>B.</given-names></name>
<name><surname>Eckstein</surname><given-names>D.</given-names></name>
<name><surname>Williams-Gray</surname><given-names>C.</given-names></name>
<name><surname>Fallon</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Parkinson’s disease and dopaminergic therapy: differential effects on movement, reward and cognition</article-title>. <source>Brain</source> <volume>131</volume>: <fpage>2094</fpage>–<lpage>2105</lpage>.</citation>
</ref>
<ref id="bibr80-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santangelo</surname><given-names>G.</given-names></name>
<name><surname>Trojano</surname><given-names>L.</given-names></name>
<name><surname>Vitale</surname><given-names>C.</given-names></name>
<name><surname>Ianniciello</surname><given-names>M.</given-names></name>
<name><surname>Amboni</surname><given-names>M.</given-names></name>
<name><surname>Grossi</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>A neuropsychological longitudinal study in Parkinson’s disease patients with and without hallucinations</article-title>. <source>Mov Disord</source> <volume>22</volume>: <fpage>2418</fpage>–<lpage>2425</lpage>.</citation>
</ref>
<ref id="bibr81-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawamoto</surname><given-names>N.</given-names></name>
<name><surname>Piccini</surname><given-names>P.</given-names></name>
<name><surname>Hotton</surname><given-names>G.</given-names></name>
<name><surname>Pavese</surname><given-names>N.</given-names></name>
<name><surname>Thielemans</surname><given-names>K.</given-names></name>
<name><surname>Brooks</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cognitive deficits and striato-frontal dopamine release in Parkinson’s disease</article-title>. <source>Brain</source> <volume>131</volume>: <fpage>1294</fpage>–<lpage>1302</lpage>.</citation>
</ref>
<ref id="bibr82-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scholtissen</surname><given-names>B.</given-names></name>
<name><surname>Verhey</surname><given-names>F.</given-names></name>
<name><surname>Adam</surname><given-names>J.</given-names></name>
<name><surname>Weber</surname><given-names>W.</given-names></name>
<name><surname>Leentjens</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Challenging the serotoninergic system in Parkinson disease patients: effects of cognition, mood and motor performance</article-title>. <source>Clin Neuropharmacol</source> <volume>29</volume>: <fpage>276</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr83-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrag</surname><given-names>A.</given-names></name>
<name><surname>Jahanshahi</surname><given-names>M.</given-names></name>
<name><surname>Quinn</surname><given-names>N.</given-names></name>
</person-group> (<year>2000</year>) <article-title>How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population</article-title>. <source>Mov Disord</source> <volume>15</volume>: <fpage>1112</fpage>–<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr84-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shohamy</surname><given-names>D.</given-names></name>
<name><surname>Adcock</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Dopamine and adaptive memory</article-title>. <source>Trend Cogn Sci</source> <volume>14</volume>: <fpage>464</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr85-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Starkstein</surname><given-names>S.</given-names></name>
<name><surname>Merello</surname><given-names>M.</given-names></name>
<name><surname>Jorge</surname><given-names>R.</given-names></name>
<name><surname>Brockman</surname><given-names>S.</given-names></name>
<name><surname>Bruce</surname><given-names>D.</given-names></name>
<name><surname>Power</surname><given-names>B.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The syndromal validity and nosological position of apathy in Parkinson’s disease</article-title>. <source>Mov Disord</source> <volume>24</volume>: <fpage>1211</fpage>–<lpage>1216</lpage>.</citation>
</ref>
<ref id="bibr86-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>H.</given-names></name>
<name><surname>Yamada</surname><given-names>M.</given-names></name>
<name><surname>Suhara</surname><given-names>T.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Functional significance of central D1 receptors in cognition: beyond working memory</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>32</volume>: <fpage>1248</fpage>–<lpage>1258</lpage>.</citation>
</ref>
<ref id="bibr87-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderploeg</surname><given-names>R.</given-names></name>
<name><surname>Schinka</surname><given-names>J.</given-names></name>
<name><surname>Retzlaff</surname><given-names>P.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Relationships between measures of auditory verbal learning and executive functioning</article-title>. <source>J Clin Exp Neuropsychol</source> <volume>16</volume>: <fpage>243</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr88-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vingerhoerts</surname><given-names>F.</given-names></name>
<name><surname>Schulzer</surname><given-names>M.</given-names></name>
<name><surname>Calne</surname><given-names>D.</given-names></name>
<name><surname>Snow</surname><given-names>B.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Which clinical sign of Parkinson’s disease reflects the nigrostriatal lesion?</article-title> <source>Ann Neurol</source> <volume>41</volume>: <fpage>58</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr89-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weintraub</surname><given-names>D.</given-names></name>
<name><surname>Koester</surname><given-names>J.</given-names></name>
<name><surname>Potenza</surname><given-names>M.</given-names></name>
<name><surname>Siderowf</surname><given-names>A.</given-names></name>
<name><surname>Stacy</surname><given-names>M.</given-names></name>
<name><surname>Voon</surname><given-names>V.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Impulse control disorders in Parkinson’s disease: a cross-sectional study of 3090 patients</article-title>. <source>Arch Neurol</source> <volume>67</volume>: <fpage>589</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr90-2045125312470130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yeterian</surname><given-names>E.</given-names></name>
<name><surname>Pandya</surname><given-names>D.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Prefrontostriatal connections in relation to cortical architectonic organisation in rhesus monkeys</article-title>. <source>J Comp Neurol</source> <volume>312</volume>: <fpage>43</fpage>–<lpage>67</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>